This work was supported by the National Natural Science Foundation of China(Nos.81873051 and 81830105);the National Science&Technology Major Project(Nos.2017ZX09301014 and 2018ZX09711001-003-007);Social Development Project of Jiangsu Provincial Science and Technology Department(BE2018711);“Double First-Class”University project(CPU 2018GF11 and CPU2018GF05);Postgraduate Research&Practice Innovation Program of Jiangsu Province(KYCX20_0657).
Hepatocellular carcinoma (HCC) is one of the most lethal tumours worldwide. However, the effects of first-line sorafenib treatment in advanced HCC fail to prolong patients’ survival due to the highly heterogeneous ch...